News Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			Pre-market 07:49:03 am
401.1 ^USD	+0.23%		409.2	+2.04%

01:09pm	Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong	MT
01:06pm	Inflation, Interest Rate Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong	07:09am	MT
Inflation, Interest Rate Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up	07:06am	MT
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	06:17am	DJ
MORNING BID AMERICAS-Relief (mostly) everywhere	05:16am	RE
S&P 500 Posts Weekly Gain as Weaker-Than-Expected April Jobs Report Boosts Hopes for FOMC Rate Cut	May. 03	MT
Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants	Apr. 26	MT
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older	Apr. 26	BU
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older	Apr. 26	CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515	Apr. 25	MT
Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics	Apr. 23	DJ
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	Apr. 23	PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	Apr. 23	AQ
TreeFrog Therapeutics SAS announced that it expects to receive $25 million in funding from Vertex Pharmaceuticals Incorporated	Apr. 22	CI
Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain	Apr. 19	AQ
Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain	Apr. 18	MT
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain	Apr. 18	BU
UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating	Apr. 17	MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445	Apr. 17	MT
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers	Apr. 15	AQ
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST